Tyrosine kinase inhibitors and development of brain metastasis in metastatic renal cell carcinoma: A retrospective review. Background: We established original methods enabling simultaneous analysis of ...
- NKT5097 is designed to selectively degrade CDK2/4 while sparing CDK1/6/7/9, enabling deep pathway inhibition - WILMINGTON, Del., December 11, 2025--(BUSINESS WIRE)--NiKang Therapeutics Inc. ("NiKang ...
WILMINGTON, Del.--(BUSINESS WIRE)--NiKang Therapeutics Inc. (“NiKang”), a clinical stage biotech company focused on developing innovative small molecule oncology medicines to help patients with unmet ...
Credit must be given to the creator. Only noncommercial uses of the work are permitted. No derivatives or adaptations of the work are permitted.
Padarn Therapeutics Inc. has described CDK2/cyclin A2 and CDK1/cyclin A2 inhibitors reported to be useful for the treatment of cancer.
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Cedilla Therapeutics, a biotechnology company bringing a new dimension to precision oncology, today revealed its two lead conditional inhibitor programs: an ...
Docetaxel versus docetaxel plus bevacizumab in progressive castration-resistant prostate cancer following first-line docetaxel. Background: We established original methods enabling simultaneous ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results